GM-CSF Oncolytic Virus and PD-1 Blockade for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods face challenges in effectively targeting and eliminating solid tumors due to weak antigenicity of tumor cells, overwhelming suppressor activities, and limited ability to generate specific immunological responses, leading to short-lived immune responses and recurrence of cancer.
Innovation Solution
A combination therapy involving the local administration of an oncolytic virus, such as CG0070, with a tumor cell-specific promoter and a heterologous gene encoding GM-CSF, and systemic administration of a PD-1 inhibitor, along with optional local and systemic immunomodulators, to enhance immune response against tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer immunotherapy methods are used, then immune response is activated, but the response is short-lived and ineffective against solid tumors due to weak antigenicity and suppressor activities
Solution Approach 1:
The oncolytic virus is administered first to infect and lyse tumor cells, releasing tumor antigens and creating an in situ vaccine. This preliminary action prepares the tumor microenvironment by breaking down immunosuppressive barriers and presenting antigens to the immune system before the PD-1 inhibitor is administered to boost the response.
Solution Approach 2:
The oncolytic virus acts as an intermediary that bridges the weak antigenicity of tumor cells and the suppressor activities. By expressing GM-CSF, the virus creates a localized immune-stimulating environment that overcomes suppression and enhances antigen presentation, making the tumor more immunogenic without requiring strong external adjuvants.
2Productivity
If nonspecific immunological components are used to boost immune response, then immune activation occurs, but the response remains short-lived and lacks specificity against tumor antigens
Solution Approach 1:
The oncolytic virus expresses GM-CSF locally at the tumor site rather than systemically. This localized expression creates a focused immune-stimulating microenvironment that specifically enhances antigen presentation and T-cell activation at the tumor location, avoiding the nonspecific and short-lived responses associated with systemic immunostimulants.
Solution Approach 2:
The oncolytic virus itself serves as both the tumor cell killer and the immune stimulator. By expressing GM-CSF, the virus performs the dual function of lysing tumor cells and simultaneously activating the immune response against released antigens, eliminating the need for separate adjuvants and achieving sustained specificity.
3Quantity of substance
If tumor cells are used as vaccines, then antigen presentation occurs, but the weak antigenicity prevents effective immune response generation
Solution Approach 1:
The oncolytic virus changes the immunogenic parameters of tumor cells by expressing GM-CSF. This cytokine expression transforms the tumor microenvironment from immunosuppressive to immunostimulating, enhancing the presentation of tumor antigens and activating dendritic cells and T-cells to mount an effective specific immune response against the weakly immunogenic tumor antigens.
Data Source
Figure 1
AI summary
The present invention provides methods for treating an individual having solid or lymphatic tumor comprising locally administering to the site of the tumor an oncolytic virus, and systemically administering an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor a second immunomodulator (including a combination of immunomodulators). Also provided are compositions and kits for the cancer therapy methods.